MosaMedix

MosaMedix is a Netherlands-based biotechnology company dedicated to the development of hypoxia-targeted radiopharmaceuticals for the treatment of solid tumors. As a spin-off from Maastricht University and MUMC+, the company leverages deep expertise in tumor microenvironments to design therapies that specifically address treatment-resistant hypoxic cancer cells. Their core technology involves Targeted Alpha Therapy (TAT), which utilizes high-energy alpha particles to induce lethal DNA damage in tumor cells while sparing adjacent healthy tissue. MosaMedix's lead candidate targets Carbonic Anhydrase IX (CAIX), a protein overexpressed in many aggressive and hypoxic cancers. The company is currently advancing its pipeline through late-stage preclinical development with the goal of addressing significant unmet needs in oncology.